Our Pipeline
Targeted Neuroprotection and Disease Modification
| Indication | Compound | Stage | Progress | Icon |
|---|---|---|---|---|
| Glaucoma | EIR-1003 | Preclinical |
Discovery → Preclinical
|
 |
| Uveal Melanoma | EIR-1004 | Preclinical |
Discovery → Preclinical
|
 |
| Stargardt Disease | EIR-0205 | Preclinical |
Discovery → Preclinical
|
 |
| Neurological Indications | Exploratory | Research |
Early Discovery
|
 |
Our lead compounds have shown efficacy in multiple preclinical models of neurodegeneration and vascular dysfunction, with evidence of:
RGC preservation and axonal regeneration post-injury
Inhibition of abnormal blood vessel proliferation
Mobilization and removal of cytotoxic retinal waste
First-in-human trials are anticipated within the next 12–18 months.